The Evolving CAR-T Therapy Supply Chain: Progress and Challenges

In by

Spotlight Article


Kimberly Lounds Foster

Supply Chain Management: PoC considerations, Product Tracking & Data Management

Kimberly Lounds FosterKimberly Lounds Foster Corporate Vice President and Head of Global Commercial Supply, Celgene, leading an integrated plan to make, source and deliver operations functions for all of Celgene’s commercial therapies including supply chain planning and logistics, internal/external manufacturing, CAR-T supply chain, Manufacturing Science & Technology along with Operations, Process and Analytics functions. Prior to Celgene, Kimberly held the position of Head of Global Supply Chain for Novartis’ Cell & Gene Therapy unit. In this role, she was responsible for building out the commercial and clinical autologous supply chain across 13 countries for CTL019. Kimberly spent over six years at Sandoz where she built the External Supplier Operations function for the North America & LatAm markets following a ‘virtual plant’ model, and managed the Sandoz US supply chain for in-line products, new product launches and US distribution centers. Kimberly holds an M.B.A from The Wharton School, University of Pennsylvania and a B.S. in Chemical Engineering from Northwestern University. Kimberly is married and lives in Morris Plains, NJ.

DOI: 10.18609/cgti.2017.085
Citation: Cell Gene Therapy Insights 2017; 3(10), 903-908.
Open access

This content is restricted to registered users. Click here to Register or Login here.